Skip to main content
Equal Safety of JAK Inhibitors and TNF Inhibitors

JAMA has published a systematic review and meta-analysis of head-to-

Dr. John Cush RheumNow

1 year ago
Equal Safety of JAK Inhibitors and TNF Inhibitors JAMA has published a systematic review and meta-analysis of head-to-head studies showing there was no meaningful difference in safety events observed when taking either JAK inhibitor (JAKi) vs TNF antagonist (TNFi) therapies for https://t.co/DTux5QdETS
When Myositis Hits the Lungs: What Every Rheumatologist Should Know About ILD

When idiopathic inflammatory myopathies

Dr. John Cush RheumNow

1 year ago
When Myositis Hits the Lungs: What Every Rheumatologist Should Know About ILD When idiopathic inflammatory myopathies (IIM) affect the lungs, the consequences can be serious. Interstitial lung disease (ILD) is not only common in IIM, but also one of the leading causes of death, https://t.co/Kxbarq9tiD
STOP-RA: Hydroxychloroquine Fails in ACPA+ Arthralgia

Deane et al has published the results of the STOP-RA trial, demo

Dr. John Cush RheumNow

1 year ago
STOP-RA: Hydroxychloroquine Fails in ACPA+ Arthralgia Deane et al has published the results of the STOP-RA trial, demonstrating that 12 months of hydroxychloroquine (HCQ) did not prevent the development of clinical RA at 36 months. https://t.co/wsnc9uZi1P https://t.co/MwZJAQs7Rt
🆕 ILD (Part II): advanced insights

🫁 Multidisciplinary management
💊 Treatment strategies
📊 Prognosis &

Dr. John Cush RheumNow

1 year ago
🆕 ILD (Part II): advanced insights 🫁 Multidisciplinary management 💊 Treatment strategies 📊 Prognosis & monitoring 🧑⚕️ What rheums should know next ⬇️ Download & learn more: https://t.co/XNmbcfqKKF Created by @MithuRheum | For our Rheum to Breathe: ILD Campaign https://t.co/Yhlw3nGsDh
Call to Update the Classification Criteria in Idiopathic Inflammatory Myopathies (IMM), Why?
- EULAR/ACR myositis criter

Dr. John Cush RheumNow

1 year ago
Call to Update the Classification Criteria in Idiopathic Inflammatory Myopathies (IMM), Why? - EULAR/ACR myositis criteria dont cover specific myositis subtypes - Polymyositis is rare - antisynthetase & necrotizing myopathy & Jo1 Dz not well represented - Need to include MSA, https://t.co/P9CEXmEOxl
SMART study - Single vs. Split Dose Methotrexate in RA

Split dose weekly, oral methotrexate (MTX) was shown to be supe

Dr. John Cush RheumNow

1 year ago
SMART study - Single vs. Split Dose Methotrexate in RA Split dose weekly, oral methotrexate (MTX) was shown to be superior to single dose MTX in treating active rheumatoid arthritis (RA) patients. https://t.co/K0C63GgHvn https://t.co/FTJ11fpKnB
Methyl-prednisolone plus methotrexate-based regime vs prednisone-based standard of care for giant cell arteritis: a prop

Luis Caminal caminalm

1 year ago
Methyl-prednisolone plus methotrexate-based regime vs prednisone-based standard of care for giant cell arteritis: a propensity score study https://t.co/kmLy6NXFO1
🎓 Learning just got smarter.
Every week, RheumIQ challenges you with a quick quiz on current rheumatology updates.
?

Dr. John Cush RheumNow

1 year ago
🎓 Learning just got smarter. Every week, RheumIQ challenges you with a quick quiz on current rheumatology updates. 💡 Educational 🎯 Evidence-based 🧠 Addictive (in a good way) Try it now and level up your clinical knowledge: https://t.co/mVZhEpn3lo https://t.co/4cMTZXxsUk
Study of urinary soluble CD163 levels in 214 SLE pts (129 w/ LN), found urinary CD163 highly correlates w/ UPCR, active

Dr. John Cush RheumNow

1 year ago
Study of urinary soluble CD163 levels in 214 SLE pts (129 w/ LN), found urinary CD163 highly correlates w/ UPCR, active vs inactive states, predicts Renal Bx histologic activity (AUC 0.962) & renal dz flares & allows prediction of complete, partial and non-responders https://t.co/HNKAuFDgPG
Controversies in ILD

This deep dive into controversies in interstitial lung disease explored complex topics including

Dr. John Cush RheumNow

1 year ago
Controversies in ILD This deep dive into controversies in interstitial lung disease explored complex topics including IPAF, methotrexate, systemic autoimmune rheumatic disease vs. connective tissue disease distinctions, and the evolving role of anti-fibrotic therapy. Panelists: https://t.co/ekP1Gg73yj
GLP-1 drugs cost-effective for knee osteoarthritis and obesity

A new study led by investigators at Mass General Brigha

Dr. John Cush RheumNow

1 year ago
GLP-1 drugs cost-effective for knee osteoarthritis and obesity A new study led by investigators at Mass General Brigham finds that adding novel weight loss GLP-1 drugs semaglutide and tirzepatide to usual care represents a cost-effective treatment strategy for people with knee https://t.co/pqWDEUgYmI
Dr. Jack Cush reviews the news and journal reports from this week on RheumNow.com. Today we cover GLP-1 agonists, acupuncture, what JAKs won’t do & an FDA Pink Slip. 
×